NVNO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.5M
+19.4%
3.8M
-6.5%
4.1M
+1.2%
4.0M
-17.8%
4.9M
R&D
2.9M
+38.5%
2.1M
-1.7%
2.1M
+8.4%
1.9M
-24.6%
2.6M
SG&A
1.7M
-3.6%
1.7M
-11.8%
2.0M
-5.5%
2.1M
-10.1%
2.3M
Operating Income
-4534000
-19.4%
-3796000
+6.5%
-4062000
-1.2%
-4013000
+17.8%
-4883000
EBITDA
-4517000
-17.1%
-3859000
+4.3%
-4031000
-1.2%
-3982000
+17.9%
-4852000
Net Income
-4367000
-21.3%
-3600000
+6.5%
-3849000
-3.0%
-3736000
+17.7%
-4539000
EPS (Basic)
$-6.29
-17.1%
$-5.37
+8.8%
$-5.89
+2.5%
$-6.04
+23.4%
$-7.89
EPS (Diluted)
$-6.29
-17.1%
$-5.37
+8.8%
$-5.89
+2.5%
$-6.04
+23.4%
$-7.89
Shares (Diluted)
694.0K
+3.4%
671.0K
+2.6%
654.0K
+5.7%
619.0K
+7.7%
575.0K
enVVeno Medical (NVNO) — Financials